A Phase 3 interventional study of Vedolizumab IV and Placebo in Crohn's Disease, sponsored by Takeda. Completed at 29 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-03-01.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.
Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 13th largest by enrollment, is one of 5 that started in 2017, is one of 16 in phase 3, and was the 25th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Austria, Belgium and 23 more countries
Ages 18–65
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 215 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 101 across the 39 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 39 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
86 studies in Crohn Disease by Takeda: 12 open now, 14 under way, 7 of them phase 3. Of 66 finished, 37 (56%) have results posted.
Among the 86 studies in Crohn Disease by Takeda, this one is the 17th largest by enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2017, is one of 25 in phase 3, and was the 31st registered.
Takeda’s Crohn Disease studies by the year they started, since 2000.
5 of the studies testing vedolizumab in Crohn Disease that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06045754TakedaA Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease | 2027-06-28 |
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 39 studies testing vedolizumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 86 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of vedolizumab intravenous (IV) infusion as induction treatment in Chinese participants with moderately to severely active Crohn's disease (CD) at Week 10.
The drug being tested in this study is called vedolizumab. Vedolizumab will be administered as an intravenous (IV) infusion in Chinese participants. This study will investigate the efficacy and safety of vedolizumab IV as induction and maintenance therapy in participants with moderately to severely active Crohn's Disease (CD).
The study will enroll approximately 300 moderately to severely active Chinese patients with CD.
Induction Phase: participants will be randomized 2:1 to receive:
Participants will receive vedolizumab 300 mg or matching placebo, intravenous (IV) infusion at Weeks 0, 2, and 6 in the induction phase. At Week 10, participants will be assessed for clinical response. Results of Week 10 clinical response will determine the treatment pathway in the maintenance phase.
Maintenance Phase: participants who achieved clinical response at Week 10 will continue to receive the same treatment as they received in Induction Phase; every 8 weeks (Q8W) starting at Week 14. Participants who received vedolizumab IV or placebo in the Induction Phase and did not achieve clinical response at Week 10 will receive vedolizumab every 4 weeks (Q4W) starting at Week 14.
This multi-center trial will be conducted in China. The overall time to participate in this study is 60 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone, 6 months after last dose of study drug for a long-term follow-up safety survey.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has moderately to severely active CD as determined by a Crohn's Disease Activity Index (CDAI) score of 220 to 400 within 7 days prior to the first dose of study drug and 1 of the following:
Has demonstrated an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents as defined below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo, IV, infusion, once at Weeks 0, 2, and 6 in the Induction Phase.
Drug: Vedolizumab IV
Vedolizumab 300 milligram (mg), IV infusion, once at Weeks 0, 2, and 6 in the Induction Phase.
Drug: Placebo
Participants who received placebo in the Induction Phase and achieved clinical response at Week 10 continued to receive placebo in the Maintenance Phase. Vedolizumab placebo-matching, IV infusion, once every 4 weeks (Q4W), from Week 14 to Week 58.
Drug: Vedolizumab IV · Drug: Placebo
Participants who received placebo in the Induction Phase and did not achieve clinical response at Week 10 received vedolizumab in the Maintenance Phase. Vedolizumab 300 mg, IV infusion, Q4W, from Week 14 to Week 58.
Drug: Vedolizumab IV
Participants who received vedolizumab in the Induction Phase and achieved clinical response at Week 10 continued to receive vedolizumab in the Maintenance Phase. Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W), at Weeks 14, 22, 30, 38, 46 and 54 and vedolizumab placebo-matching, IV infusion, Q8W, at Weeks 18, 26, 34, 42, 50 and 58 to maintain double-blind.
Drug: Placebo
Participants who received vedolizumab in the Induction Phase and did not achieve clinical response at Week 10 received vedolizumab in the Maintenance Phase. Vedolizumab 300 mg, IV infusion, Q4W, from Week 14 to Week 58.
Drug: Vedolizumab IV
Vedolizumab IV infusion
Vedolizumab placebo-matching
Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10
Enhanced clinical response was defined as ≥100-point decrease from Baseline in the Crohn's Disease Activity Index (CDAI) score at Week 10. A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score is equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.
Time frame: Week 10
Percentage of Participants With Clinical Remission in the Induction Phase at Week 10
Clinical remission was defined as CDAI score of ≤150 points at Week 10. A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score is equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity
Time frame: Week 10
Participants took part in the study at 27 investigative sites in China from 3 August 2017 to 14 August 2020.
| Milestone | Induction Phase: Placebo | Induction Phase: Vedolizumab 300 mg | Maintenance Phase: Induction Placebo to Placebo Q4W | Maintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4W | Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8W | Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W |
|---|---|---|---|---|---|---|
| Started | 71 | 144 | 0 | 0 | 0 | 0 |
| Treated | 70 | 144 | 0 | 0 | 0 | 0 |
| Completed | 61 | 138 | 0 | 0 | 0 | 0 |
| Not completed | 10 | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Enrolled but not treated | 1 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Induction Phase: Placebo | Induction Phase: Vedolizumab 300 mg | Maintenance Phase: Induction Placebo to Placebo Q4W | Maintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4W | Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8W | Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 18 | 38 | 46 | 88 |
| Completed | 0 | 0 | 17 | 27 | 36 | 67 |
| Not completed | 0 | 0 | 1 | 11 | 10 | 21 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 4 | 3 | 7 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 3 | 3 | 4 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 4 | 4 | 10 |
Enhanced clinical response was defined as ≥100-point decrease from Baseline in the Crohn's Disease Activity Index (CDAI) score at Week 10. A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score is equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.
| percentage of participants | Induction Phase: Placebo | Induction Phase: Vedolizumab 300 mg |
|---|---|---|
| Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10 | 24.3 (14.8 to 36.0) | 19.4 (13.3 to 26.9) |
Clinical remission was defined as CDAI score of ≤150 points at Week 10. A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score is equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity
| percentage of participants | Induction Phase: Placebo | Induction Phase: Vedolizumab 300 mg |
|---|---|---|
| Percentage of Participants With Clinical Remission in the Induction Phase at Week 10 | 11.4 (5.1 to 21.3) | 9.0 (4.9 to 14.9) |
Collected over From first dose of the study drug up to 18 weeks after the last dose (Induction Phase: Up to Week 28; Maintenance Phase: Up to Week 78). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction Phase: Placebo | 0/70 (0%) | 5/70 (7.1%) | 26/70 (37.1%) |
| Induction Phase: Vedolizumab 300 mg | 0/144 (0%) | 12/144 (8.3%) | 60/144 (41.7%) |
| Maintenance Phase: Induction Placebo to Placebo Q4W | 0/18 (0%) | 3/18 (16.7%) | 12/18 (66.7%) |
| Maintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4W | 0/38 (0%) | 10/38 (26.3%) | 23/38 (60.5%) |
| Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8W | 0/46 (0%) | 14/46 (30.4%) | 27/46 (58.7%) |
| Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W | 1/88 (1.1%) | 25/88 (28.4%) | 63/88 (71.6%) |
| Event | Induction Phase: Placebo | Induction Phase: Vedolizumab 300 mg | Maintenance Phase: Induction Placebo to Placebo Q4W | Maintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4W | Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8W | Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W |
|---|---|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 0/70 | 4/144 | 1/18 | 5/38 | 9/46 | 7/88 |
| Small intestinal obstructionGastrointestinal disorders | 0/70 | 0/144 | 1/18 | 0/38 | 0/46 | 1/88 |
| Anal abscessInfections and infestations | 1/70 | 1/144 | 1/18 | 0/38 | 1/46 | 2/88 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/70 | 0/144 | 0/18 | 0/38 | 2/46 | 0/88 |
| Intestinal obstructionGastrointestinal disorders | 0/70 | 0/144 | 0/18 | 0/38 | 0/46 | 3/88 |
| Abdominal painGastrointestinal disorders | 1/70 | 0/144 | 0/18 | 1/38 | 0/46 | 0/88 |
| Anal fistulaGastrointestinal disorders | 0/70 | 1/144 | 0/18 | 1/38 | 0/46 | 1/88 |
| Gastrointestinal fistulaGastrointestinal disorders | 1/70 | 0/144 | 0/18 | 1/38 | 0/46 | 1/88 |
| HaematocheziaGastrointestinal disorders | 0/70 | 2/144 | 0/18 | 1/38 | 0/46 | 1/88 |
| AnaemiaBlood and lymphatic system disorders | 0/70 | 0/144 | 0/18 | 1/38 | 0/46 | 2/88 |
| Event | Induction Phase: Placebo | Induction Phase: Vedolizumab 300 mg | Maintenance Phase: Induction Placebo to Placebo Q4W | Maintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4W | Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8W | Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W |
|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 2/70 | 13/144 | 3/18 | 2/38 | 6/46 | 11/88 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/70 | 0/144 | 3/18 | 2/38 | 1/46 | 7/88 |
| Upper respiratory tract infectionInfections and infestations | 3/70 | 11/144 | 0/18 | 4/38 | 5/46 | 12/88 |
| Blood urine presentInvestigations | 0/70 | 0/144 | 0/18 | 5/38 | 1/46 | 8/88 |
| AnaemiaBlood and lymphatic system disorders | 6/70 | 8/144 | 2/18 | 2/38 | 6/46 | 10/88 |
| Mouth ulcerationGastrointestinal disorders | 3/70 | 10/144 | 1/18 | 1/38 | 2/46 | 10/88 |
| Protein urine presentInvestigations | 5/70 | 13/144 | 1/18 | 3/38 | 4/46 | 10/88 |
| NasopharyngitisInfections and infestations | 6/70 | 14/144 | 1/18 | 2/38 | 2/46 | 10/88 |
| Abdominal painGastrointestinal disorders | 0/70 | 0/144 | 2/18 | 0/38 | 1/46 | 6/88 |
| Lymphocyte count decreasedInvestigations | 7/70 | 8/144 | 2/18 | 3/38 | 4/46 | 3/88 |
FAS for the induction phase study included all randomized participants who received any amount of blinded study drug during the Induction Phase.
| Age, Continuous(years) | Induction Phase: Placebo | Induction Phase: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Mean | 31.1 ± 8.12 | 31.1 ± 10.10 | 31.1 ± 9.48 |
| Sex: Female, Male(Participants) | Induction Phase: Placebo | Induction Phase: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Female | 16 | 48 | 64 |
| Male | 54 | 96 | 150 |
| Ethnicity (NIH/OMB)(Participants) | Induction Phase: Placebo | Induction Phase: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 70 | 144 | 214 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Induction Phase: Placebo | Induction Phase: Vedolizumab 300 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 70 | 144 | 214 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Weight(kg) | Induction Phase: Placebo | Induction Phase: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Mean | 54.61 ± 10.662 | 54.33 ± 10.388 | 54.42 ± 10.454 |
| Height(cm) | Induction Phase: Placebo | Induction Phase: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Mean | 168.18 ± 7.785 | 166.96 ± 8.064 | 167.36 ± 7.976 |
| Body Mass Index (BMI)(kg/m^2) | Induction Phase: Placebo | Induction Phase: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Mean | 19.21 ± 2.978 | 19.38 ± 2.742 | 19.33 ± 2.815 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Aug 2017 to primary completion in Aug 2020, 36 months.
Results were first posted in Sep 2022, 2 years 1 month after primary completion. A results delay was requested in Jul 2021.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 36 months is below that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab